Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects
Brief Summary: The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.


Options:
A: Inclusion Criteria:

* proved SARS-COVID-2 infection

Exclusion Criteria:

* none
B: Inclusion Criteria:

* ≥ 18 years of age
* Hospitalized for COVID-19
* Enrolled within 72 hours of hospital admittance or 72 hours of positive COVID test
* Expected to require hospitalization for \> 72 hours

Exclusion Criteria:

* Imminent death
* Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
* Pregnancy

Inclusion Criteria for Arm E

Inclusion criteria contained in the master protocol in addition to the following:

Moderate illness severity - defined as non-ICU level of care at the time of randomization (not receiving high flow nasal oxygen (HFNO), non-invasive ventilation (NIV), invasive ventilation (IV), vasopressors or inotropes, or extracorporeal membrane oxygenation (ECMO) OR Severe illness severity - defined as ICU level of care at the time of randomization (receiving HFNO, NIV, IV, vasopressors or inotropes, or ECMO)

For moderate illness severity, participants are required to meet one or more of the following risk criteria:

1. Age ≥ 65 years or
2. ≥2 of the following -

   * O2 supplementation \> 2 liters per minute
   * BMI ≥ 35
   * GFR ≤ 60
   * History of Type 2 diabetes
   * History of heart failure (regardless of ejection fraction)
   * D dimer ≥ 2x the site's upper limit of normal (ULN)
   * Troponin ≥ 2x the site's ULN
   * BNP≥100 pg/mL or NT-proBNP≥300 pg/mL
   * CRP ≥50 mg/L

Exclusion Criteria for Arm E

* Exclusion criteria contained in the master protocol, and
* Any condition that, in the opinion of the investigator, precludes the use of crizanlizumab such as uncontrolled bleeding or severe anemia (hemoglobin\<4 g/dL)
* Open label treatment with crizanlizumab within the past three months

Inclusion Criteria for Arm F

Inclusion criteria contained in the master protocol in addition to the following:

Moderate illness severity - defined as non-ICU level of care at the time of randomization (not receiving high flow nasal oxygen (HFNO), non-invasive ventilation (NIV), invasive ventilation (IV), vasopressors or inotropes, or extracorporeal membrane oxygenation (ECMO)) OR Severe illness severity - defined as ICU level of care at the time of randomization (receiving HFNO, NIV, IV, vasopressors or inotropes, or ECMO)

For moderate illness severity, participants are required to meet one or more of the following risk criteria:

1. Age ≥ 65 years or
2. ≥2 of the following-

   * O2 supplementation \> 2 liters per minute
   * BMI ≥ 35
   * GFR ≤ 60
   * History of Type 2 diabetes
   * History of heart failure (regardless of ejection fraction)
   * D dimer ≥ 2x the site's upper limit of normal (ULN)
   * Troponin ≥ 2x the site's ULN
   * BNP≥100 pg/mL or NT-proBNP≥300 pg/mL
   * CRP ≥50 mg/L

Exclusion Criteria for Arm F

In addition to the exclusion criteria noted in the master protocol, arm-specific exclusion criteria are as follows:

* Known hypersensitivity to any SGLT2 inhibitors
* Type 1 diabetes
* History of diabetic ketoacidosis
* eGFR \<20 and/or requirement for renal replacement therapy
* Open label treatment with any SGLT2 inhibitor

  * Based on a recommendation from the ACTIV4 DSMB on December 19, 2020, enrollment of patients requiring ICU level of care into the therapeutic anti-coagulation arm was stopped due to meeting a futility threshold and a potential for harm for this sub-group could not be excluded. Enrollment continues for moderately ill hospitalized COVID-19 patients.
  * Based on a recommendation from the ACTIV4 DSMB on June 18, 2021, enrollment of patients not requiring ICU level of care and randomized to P2Y12 or standard care was stopped due to meeting a futility threshold. Enrollment continues for severely ill (ICU level of care) hospitalized COVID-19 patients.
C: Men and women with early carotid atherosclerosis and moderately elevated LDL cholesterol between the 60th and 90th percentiles.
D: Inclusion Criteria:

* Provision of informed consent prior to any study-specific procedures
* Male aged ≥45 and \<70 years or female aged ≥55 and \<70 years
* Subjects with only hypertension (as defined blood pressure ≥140/90 mmHg or on antihypertensive treatment) and age as CVD risk factors and subjects without hypertension who have 3 or more other risk factors (including age) must have "Fasting LDL C of ≥120 mg/dL (3.1 mmol/L) and \<160 mg/dL (4.1mmol/L)"; Subjects without hypertension who have fewer than 3 other risk factors (including age) must have "Fasting LDL-C of ≥120 mg/dL (3.1 mmol/L) and \<190 mg/dL (4.9 mmol/L)"
* Triglycerides \<500 mg/dL (5.65 mmol/L) at Visit 1
* HDL-C levels ≤60 mg/dL (1.6 mmol/L) at Visit 1
* Maximum IMT ≥1.2 mm and \<3.5 mm at any location in the carotid ultrasound scans conducted at both Visit 2 and Visit 3
* Willing to follow all study procedures including study visits, fasting blood draws, and compliance with study treatment regimen

Exclusion Criteria:

* Use of pharmacologic lipid-lowering medications (eg, statins, fibrate derivatives,bile acid binding resins, niacin, or its analogues at doses \>400 mg or prescribed Chinese traditional drugs), including cholesterol-absorption inhibitors (CAIs), and CAI/statin combination, within 12 months prior to Visit 1
* Current or recent (within 2 weeks of Visit 1) use of supplements known to alter lipid metabolism (eg, soluble fibers \[including \>2 teaspoons Metamucil® or psyllium-containing supplement per day\] or other dietary fiber supplements, marine oils, sterol/stanol products, or other supplement determined at the discretion of the investigator)
* History of hypersensitivity reactions to other HMG-CoA reductase inhibitors
* Pregnant women, women who are breast-feeding, and women of childbearing potential who are not using chemical or mechanical contraception or who have a positive serum pregnancy test
* Clinical evidence of coronary artery disease (CAD) or any other atherosclerotic disease such as angina, MI, transient ischemic attack, symptomatic CAD, cerebrovascular accident, percutaneous coronary intervention, coronary artery bypass graft, peripheral arterial disease, abdominal aortic aneurysm
* History of cancer (other than basal cell carcinoma) in the past 2 years
* Uncontrolled hypertension defined as either a mean resting diastolic blood pressure of ≥110 mmHg or a resting systolic blood pressure of ≥180 mmHg recorded at any time during the screening period
* History of diabetes mellitus or current diabetes mellitus
* Uncontrolled hypothyroidism defined as a thyroid stimulating hormone (TSH) \>1.5 times the upper limit of normal (ULN) at Visit 1 or subjects whose thyroid replacement therapy was initiated within the last 3 months
* History of heterozygous or homozygous familial hypercholesterolemia or known hyperlipoproteinemia Types I, III, IV, or V (familial dysbetalipoproteinemia)
* Use of the disallowed concomitant medications within 12 months prior to Visit 1
* History of alcohol and/or drug abuse within the past 5 years
* Active liver disease or hepatic dysfunction as defined by elevations of ≥1.5 x ULN at Visit 1 in any of the following liver function tests: ALT, AST or bilirubin
* Serum creatine kinase (CK) \>3 x ULN at Visit 1
* Serum creatinine \>2.0 mg/dL (177 mmol/L) recorded during the screening period
* Participation in another investigational drug study, and having ingested investigational drug ≤4 weeks before enrollment in the screening period
* Previous randomization in the present study
* History of a significant medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)

Answer: D